Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy ...Middle East

NEW YORK, March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of...

Hence then, the article about hoth therapeutics announces collaboration with first active clinical site for its phase 2 trial to treat cancer disorders associated with epidermal growth factor receptor egfr inhibitor therapy was published today ( Wednesday 08/03/2023 - 05:21 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy )

Also on site :

• Travel Warning Issued For Millions Across US
• ‘Change is inevitable’: What is next for Iran?
• Australian Open: Sinner overcomes cramps; Keys, Pegula advance; Osaka withdraws